Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22910244 | 0.95 | AAK1 (0.30) | AAK1 | |
| SCHEMBL25484221 | 0.73 | SORD (0.30) | — | |
| SCHEMBL25484449 | 0.71 | — | — | |
| SCHEMBL21347898 | 0.68 | AAK1 (0.36) | AAK1 | |
| SCHEMBL21347897 | 0.68 | MCOLN2 (0.36) | — | |
| SCHEMBL3298801 | 0.66 | IDH1 (0.37) | AAK1 | |
| SCHEMBL25099144 | 0.63 | SORD (0.34) | — | |
| SCHEMBL25933602 | 0.63 | HRH4 (0.35) | — | |
| SCHEMBL22927476 | 0.62 | ALDH1A1 (0.35) | — | |
| SCHEMBL26532695 | 0.62 | CYP3A4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2023-01-26 | — | — | US | disclosed |
| US-11560376-B2 | Amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11419869-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20200352942-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| US-10793564-B2 | Amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190276449-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | AAK1 3653/4885 |
| US-11419869-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | AAK1 4108/4885 |
| US-10793564-B2 | Amino acid compounds and methods of use | ITGB6, ITGA6, ITGA5 | AAK1 3653/4885 |
| US-20190276449-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | AAK1 3653/4885 |
| US-20200352942-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | ITGB6, ITGA6, ITGAV | AAK1 4108/4885 |
| US-11560376-B2 | Amino acid compounds and methods of use | ITGB6, ITGA6, ITGA5 | AAK1 3653/4885 |
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | ITGB6, ITGAV, ITGA6 | AAK1 4320/4885 |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | ITGA5, ITGAL, ITGB5 | AAK1 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.